-
Carbapenemase Transmission in CREC in Guangdong
2026-08-18
Chen et al. combine gene localization, antimicrobial susceptibility testing, conjugation assays, mobile-element profiling, and ERIC-PCR to examine carbapenem-resistant Enterobacter cloacae across eight teaching hospitals. The study identifies plasmid-associated blaNDM-1 as a dominant and highly transferable resistance determinant, while also showing that local clonal relatedness and patient-care settings both matter for surveillance and infection-control planning.
-
Anlotinib: VEGFR2 Inhibition in Tumor Angiogenesis
2026-08-18
The reference study established anlotinib as a highly potent, selective VEGFR2 inhibitor whose biochemical activity translated into endothelial signaling blockade, impaired angiogenesis, and antitumor efficacy in preclinical models. Its experimental design connects kinase selectivity with cellular, ex vivo, and in vivo endpoints, while also clarifying why vascular inhibition rather than direct tumor-cell cytotoxicity is the principal mechanism.
-
Spermine C4910 for Reproducible Cell Assays
2026-08-17
This scenario-based guide explains how Spermine, an endogenous polyamine, can be evaluated in cell viability, proliferation, cytotoxicity, and ion-channel workflows. It provides practical guidance for using SKU C4910, including concentration logic, solvent controls, storage, interpretation, and vendor-selection criteria.
-
NHS-Biotin for Translational Protein Engineering
2026-08-17
NHS-Biotin connects precise amine-reactive labeling with modern protein assembly strategies, helping translational researchers characterize nanobody multimers, optimize detection workflows, and plan more reproducible purification and cell-based studies.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-08-16
FITC-Concanavalin A (ConA) Conjugate, SKU K4413, provides fluorescence-based detection of α-D-glucose and α-D-mannose moieties on glycoproteins and glycolipids in cell, tissue, microscopy, and flow cytometry workflows. It is intended for carbohydrate-binding analysis and should not be used as a general stain for non-carbohydrate targets or outside the specified storage and light-protection conditions.
-
Z-VEID-FMK: Caspase-6 Inhibitor Workflow
2026-08-15
Z-VEID-FMK provides a cell-permeable, irreversible way to test whether caspase-6 contributes to apoptotic phenotypes. This workflow also shows how to separate caspase-6-dependent apoptosis from the caspase-1-driven pyroptosis reported in lung cancer research.
-
Chloroquine BA1002: Practical Research Workflow
2026-08-14
This guide explains how to prepare, dose, and QC Chloroquine (SKU BA1002) for cell-based autophagy, immune-pathway, anticancer, antiviral, malaria, and rheumatoid arthritis research. It supports controlled in vitro workflow design but should not be used to infer clinical dosing, selective pathway effects, or efficacy for an unvalidated model.
-
Bestatin (Ubenimex) in Aminopeptidase Workflows
2026-08-14
Bestatin (Ubenimex) connects enzyme-selective aminopeptidase inhibition with practical cell-based studies of apoptosis, multidrug resistance, and cancer biology. This guide shows how to move from activity measurement to phenotype while controlling solubility, exposure, assay specificity, and interpretation.
-
VER 155008: HSP 70 Inhibitor Workflows
2026-08-13
VER 155008 connects biochemical measurement of Hsp70 ATPase activity with cell-based studies of apoptosis and cancer cell proliferation inhibition. This guide shows how to control solvent effects, separate cytostasis from cell death, and extend chaperone biology into a carefully bounded TDP-43 condensate model.
-
HyperScript™ RT SuperMix for qPCR: 5 Lab Scenarios
2026-08-13
This scenario-driven guide explains how HyperScript™ RT SuperMix for qPCR, SKU K1074, can support reproducible cDNA synthesis for viability, proliferation, cytotoxicity, and cancer-stemness studies. It connects formulation features with practical decisions involving low-input RNA, complex templates, qRT-PCR controls, interpretation, and vendor selection.
-
X-press Tag Peptide in RHEB Signaling Research
2026-08-12
A translational perspective on using X-press Tag Peptide as an N-terminal leader peptide to connect recombinant protein purification, orthogonal detection, and mechanistic studies of the UBE2F–SAG–RHEB–mTORC1 axis.
-
3D Organoid–Fibroblast Models of PDAC Chemoresistance
2026-08-12
Schuth and colleagues developed a patient-specific three-dimensional co-culture system that combines pancreatic ductal adenocarcinoma organoids with matched cancer-associated fibroblasts. The model revealed increased tumor-cell proliferation, reduced chemotherapy-induced death, and stromal induction of inflammatory and epithelial-to-mesenchymal transition programs, showing why epithelial-only organoids can underestimate microenvironment-mediated drug resistance.
-
Targeted Amikacin Delivery into Mycobacterial Granulomas
2026-08-11
Montes-Worboys and colleagues developed a dendritic-cell delivery strategy to direct fluorescently labeled amikacin into Mycobacterium avium granulomas in infected mice. The study provides proof-of-concept for localized aminoglycoside delivery, while also showing that the modified drug retained comparable antimycobacterial activity and did not produce the measured inflammatory signal.
-
Cycloastragenol Protects Against GIONFH in Rats
2026-08-11
This in vivo study shows that cycloastragenol limits methylprednisolone-associated femoral-head damage in rats by suppressing osteoclast activity, preserving trabecular bone, and improving local blood supply. Its value is mechanistic as well as therapeutic: the findings position the RANKL/OPG axis and osteoclast-resorption program as measurable targets for hip-preservation research, while still requiring validation beyond the animal model.
-
TH287 Radiosensitizes Castration-Resistant Prostate Cancer
2026-08-10
The reference study shows that TH287 can enhance ionizing-radiation responses in PC-3 and DU-145 castration-resistant prostate cancer cells, with the strongest effect when radiation follows initial inhibitor exposure by 12 hours. Its main innovation is the treatment-schedule analysis, supported by survival, apoptosis, protein-expression, and cell-cycle measurements.